Fesoterodine
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Fesoterodine and local guidelines before prescribing.
Antimuscarinic
Mechanism
Antimuscarinic.
Uses
Overactive bladder.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Dry mouth, constipation, urinary retention.
Interactions
CYP3A4 and 2D6 inhibitors.
Contraindications and cautions
Urinary retention, glaucoma
Monitoring
Bladder emptying
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Reduce dose in renal and hepatic impairment
Overdose and reversal
Supportive
Special advice
Avoid in cognitively impaired older people.
More from the textbook: uses, cautions and other points
- Antimuscarinics (oxybutynin, solifenacin, tolterodine, trospium, fesoterodine) - dry mouth, constipation, blurred vision, urinary retention; confusion and possible dementia risk in older people (avoid immediate-release oxybutynin in frail older women; trospium crosses into the brain less).
Renal: Anatomy, Physiology and Pharmacology - Solifenacin / tolterodine / fesoterodine | Antimuscarinics for overactive bladder; dry mouth, constipation; anticholinergic burden in older people.
Gynaecology: Pelvic floor ovary and vulva
Where it is discussed in the book
- Renal: Anatomy, Physiology and Pharmacology (1 mention)
- Gynaecology: Pelvic floor ovary and vulva (1 mention)